Phase XS is a unique analytical platform, which helps you to plan your strategy for biosimilar and biologics development. It is a proprietary tool of Coherent Market Insights (CMI) that aims to provide meticulous details of clinical trials (Phase 3 and Phase 4) conducted in the U.S. along with the analytical insights from the team of CMI consultants and verified by industry experts.

TRACKING 25+ CRITICAL PARAMETERS

Line break

CHANGING PRODUCT MIX

CHANGING PRODUCT MIX

CHANGING PRODUCT MIX

FOCUS SHIFT

FOCUS SHIFT

Line break

REGULATORY SUPPORT

The U.S. FDA accelerated approvals of biosimilars from 2016. It approved five new biosimilars in 2017 as against one in 2015. Around US$ 46 Bn worth of biologics are expected to go off-patent by 2022. Therefore, it is of critical importance to analyze your competition and decide your market entry before it’s too late. Furthermore, the U.S. FDA works in collaboration with sponsors to evaluate and suggest for any flexibility in clinical trial design. Moreover, biosimilars need to prove clinical safety and efficacy in head-to-head comparative studies with the reference product. PHASE-XS encompass information about clinical trial design for phase 3 biologics and biosimilars to support your clinical trial planning.

biosimilars approvals in us

PHASE-XS BENEFITS AND POTENTIAL GAINERS

Benefits

  • Identify the potential competitors of future
  • Identify target products for biosimilars through patent expiry details
  • Identify indication extension of already approved biologics
  • Identify the white spaces
  • Identify the products with significant revenue opportunity
  • Identify an ideal trail design possessing a competitive edge
  • Identify addressable patient pool
  • Get actionable market insights

Apt solution for

  • One who is planning to develop/developing biosimilars
  • One who desires to increase its market share
  • One who needs to understand the future competition
  • One who wants to develop a biologic/biosimilar with no/less competition
  • One who needs to identify niche/less competitive segments for biologics/biosimilar
  • One who needs to know the technology (protein extract, mAbs, DNA/RNA therapeutics, ETC.) behind specific biologics
  • One who needs to understand the potential of specific target segments/molecules
  • Supplier of APIs

Get In Touch